Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Other financing activities (2017 - 2023)

PharmaCyte Biotech (PMCB) has disclosed Other financing activities for 10 consecutive years, with $2.3 million as the latest value for Q3 2023.

  • Quarterly Other financing activities rose 82211.45% to $2.3 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Jul 2023, up 9030.67% year-over-year, with the annual reading at $7334.0 for FY2023, 77.87% down from the prior year.
  • Other financing activities for Q3 2023 was $2.3 million at PharmaCyte Biotech, up from $667.0 in the prior quarter.
  • The five-year high for Other financing activities was $2.3 million in Q3 2023, with the low at $667.0 in Q1 2023.
  • Average Other financing activities over 5 years is $165341.4, with a median of $48187.5 recorded in 2019.
  • Peak annual rise in Other financing activities hit 82211.45% in 2023, while the deepest fall reached 91.95% in 2023.
  • Over 5 years, Other financing activities stood at $104727.0 in 2019, then plummeted by 35.72% to $67320.0 in 2020, then tumbled by 83.58% to $11055.0 in 2021, then tumbled by 64.57% to $3917.0 in 2022, then surged by 57688.23% to $2.3 million in 2023.
  • According to Business Quant data, Other financing activities over the past three periods came in at $2.3 million, $667.0, and $3917.0 for Q3 2023, Q1 2023, and Q4 2022 respectively.